AstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug Conjugates Across Tumour Types; Summit And AstraZeneca Have Also Entered Into A Clinical Collaboration Agreement To Evaluate Sonesitatug Vedotin In Combination With Ivonescimab
https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html
Share
Why It Matters
AstraZeneca is putting $2 billion into Summit to develop a new cancer medicine. This shows AstraZeneca thinks the medicine could be really valuable and worth betting on.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.